Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) have received a consensus recommendation of “Buy” from the six analysts that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation, four have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $55.60.

A number of brokerages have recently weighed in on TARS. The Goldman Sachs Group lifted their price target on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a “neutral” rating in a report on Friday, November 15th. Oppenheimer upped their price target on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an “outperform” rating in a research note on Wednesday.

Institutional Trading of Tarsus Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the stock. Allspring Global Investments Holdings LLC lifted its position in shares of Tarsus Pharmaceuticals by 16.3% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 210,531 shares of the company’s stock worth $6,924,000 after acquiring an additional 29,465 shares during the period. JPMorgan Chase & Co. raised its holdings in shares of Tarsus Pharmaceuticals by 2,088.8% in the third quarter. JPMorgan Chase & Co. now owns 440,167 shares of the company’s stock valued at $14,477,000 after buying an additional 420,057 shares during the last quarter. Creative Planning acquired a new position in shares of Tarsus Pharmaceuticals during the third quarter worth approximately $362,000. Vestal Point Capital LP acquired a new position in Tarsus Pharmaceuticals during the 3rd quarter worth $7,565,000. Finally, Essex Investment Management Co. LLC acquired a new position in Tarsus Pharmaceuticals during the 3rd quarter valued at about $3,590,000. 90.01% of the stock is owned by institutional investors.

Tarsus Pharmaceuticals Stock Performance

Shares of NASDAQ TARS opened at $48.78 on Friday. The stock’s fifty day simple moving average is $51.04 and its 200 day simple moving average is $38.94. The stock has a market capitalization of $1.86 billion, a price-to-earnings ratio of -12.80 and a beta of 1.02. The company has a quick ratio of 5.38, a current ratio of 5.42 and a debt-to-equity ratio of 0.30. Tarsus Pharmaceuticals has a 52-week low of $20.08 and a 52-week high of $57.14.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.